POM-V Prescription Required Companion Animal

Prednizol 5 mg Tablets for Dogs and Cats

Active ingredient: Prednisolone

Form

Tablet

Species

Cats Dogs

Manufacturer

Millpledge Europe BV

VMD MA No.

61300/3005

What it's used for

For the symptomatic treatment of inflammatory or allergic conditions in dogs and cats.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Prednisolone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Prednizol 5 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the symptomatic treatment of inflammatory or allergic conditions in dogs and
cats.

For oral administration 0.1 - 2.0 mg per kg bodyweight per day. The dose and total
duration of treatment is determined by the veterinarian per individual case depending
on the severity of symptoms. The lowest effective dose must be used.
For longer term treatment: when after a period of daily dosing, the desired effect has
been achieved, the dose should be reduced until the lowest effective dose is
reached. The reduction of the dose should be made by alternate day therapy and/or
by halving the dose with intervals of 5 - 7 days, until the lowest effective dose is
reached. The tablets are not intended to be divided. For animals requiring a dose
below 5 mg an alternative or lower strength product should be used.
Dogs should be treated in the morning and cats in the evening on account of
differences in day rhythm.

Do not use in animals with:
•
treatment
•
•
•
•
•
•
•
•
Do not use concomitantly with attenuated live vaccines.
Do not use in known cases of hypersensitivity to the active substance, to other
corticosteroids, or to any of the excipients.

Revised: August 2025
AN: 01405/2025
See also sections 4.7 and 4.8.

Anti-inflammatory corticosteroids, such as prednisolone, are known to exert a wide
range of side effects. Whilst single high doses are generally well tolerated, they may
induce severe side-effects in long term use.
The significant dose related cortisol suppression noticed during therapy is a result of
effective doses suppressing the hypothalamic-pituitary-adrenal-axis. Following
cessation of treatment, signs of adrenal insufficiency can arise and this may render
the animal unable to deal adequately with stressful situations.
The significant increase in triglycerides noticed can be a part of possible iatrogenic
hyperadrenocorticism (Cushing’s disease) involving significant alteration of fat,
carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat,
increase in body weight, muscle weakness, wastage and osteoporosis may result.
Cortisol suppression and an increase in plasma triglycerides is a very common side-
effect of medication with corticoids (more than 1 in 10 animals).
Changes in biochemical, haematological and liver parameters probably associated
with the use of prednisolone were significant effects noticed on alkaline phosphatase
(increase), lactate dehydrogenase (decrease), albumin (increase), eosinophils,
lymphocytes (decrease), segmented neutrophils (increase), alkaline phosphatase
(increase) and serum hepatic enzymes (increase). A decrease in aspartate
transaminase is also noticed.
Systemically administered corticosteroids may cause polyuria, polydipsia and
polyphagia, particularly during the early stages of therapy. Some corticosteroids may
cause sodium and water retention and hypokalaemia in long term use. Systemic
corticosteroids have caused deposition of calcium in the skin (calcinosis cutis).
Corticosteroid use may delay wound healing and the immunosuppressant actions
may weaken resistance to or exacerbate existing infections.
Gastrointestinal ulceration has been reported in animals treated with corticosteroids
and gastrointestinal ulceration may be exacerbated by steroids in animals given non-
steroidal anti-inflammatory drugs and in animals with spinal cord trauma.
Other adverse reactions that may occur are: inhibition of longitudinal growth of
bones; skin atrophy; diabetes mellitus; behavioural disorders (excitation and
depression), pancreatitis, decrease in thyroid hormone synthesis; increase in
parathyroid hormone synthesis. See also section 4.7.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports)

Glucocorticoids can produce symptomatic improvements without treating the
underlying disease. Where appropriate, use of the product should be combined with
treatment of the underlying disease and/or management of the affected animal’s
environment.

Special precautions for use in animals
In cases where a bacterial infection is present the product should be used in
association with suitable antibacterial therapy.
Corticoids such as prednisolone should be used with caution in patients with
hypertension, epilepsy, burns, previous steroid myopathy, in immunocompromised
animals and in young animals as corticosteroids may induce a delayed growth.
Corticoids such as prednisolone, exacerbate proteinaceous catabolism.
Consequently, the product should be carefully administered in old or malnourished
animals.
Special monitoring is required in animals presenting with renal insufficiency. Use only
after careful benefit-risk assessment by the responsible veterinarian.
Pharmacologically-active dose levels may lead to atrophy of the adrenal cortex,
resulting in adrenal insufficiency. This may become apparent particularly after
withdrawal of corticosteroid treatment. In order to minimise the chance of adrenal
insufficiency, the lowest effective dose should be used and at the end of treatment
the dose used should be gradually reduced. Treatment should not be suddenly
withdrawn. This is especially important following medium or long term treatment.
Some cases may require continuing therapy, and in this situation the minimum
effective maintenance dose should be established. It is generally considered that
problems associated with the induction of adrenal insufficiency are minimised by
dosing once every alternate morning for dogs and every alternate evening for cats.
See also section 4.8.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Pharmacological effects of prednisolone cannot be excluded following accidental
ingestion of the product. The product is supplied in a container with a child-resistant
closure, and in blisters. The cap of the container must be securely engaged after use.
If smaller quantities are dispensed from the pack, they must be supplied in a
container with a child-resistant closure. If appropriate containers are not available,
the product must be supplied in the original container. Store the product safely, out of
the sight and reach of children.
In case of accidental ingestion seek medical attention and show product label and/or
package leaflet to the doctor.
Immediately wash hands thoroughly after handling the tablets.
People with known hypersensitivity to prednisolone or other corticosteroids should
avoid contact with the veterinary medicinal product.
Corticosteroids can cause foetal malformations; therefore, it is recommended that
pregnant women avoid contact with the veterinary medicinal product.

Revised: August 2025
AN: 01405/2025

Phenytoin, barbiturates, ephedrine and rifampicin may accelerate the metabolic
clearance of corticosteroids resulting in decreased blood levels and reduced
physiological effect.
The concomitant use of this veterinary medicinal product with non-steroidal anti-
inflammatory drugs may exacerbate gastrointestinal tract ulceration.
Administration of prednisolone may induce hypokalaemia and hence increase the
risk of toxicity from cardiac glycosides. The risk of hypokalaemia may be increased if
prednisolone is administered together with potassium depleting diuretics.
Precautions need to be taken when combining use with insulin.
Because corticosteroids can reduce the immune response to vaccination, a two week
interval in treatment with the veterinary medicinal product should be observed before
and after vaccination.

This veterinary medicinal product does not require any special storage conditions.

Revised: August 2025
AN: 01405/2025

4. CLINICAL PARTICULARS
4.1 Target species
Dogs and cats
4.2 Indications for use, specifying the target species
For the symptomatic treatment of inflammatory or allergic conditions in dogs and
cats.
4.3 Contraindications
Do not use in animals with:
•
treatment
•
•
•
•
•
•
•
•
Do not use concomitantly with attenuated live vaccines.
Do not use in known cases of hypersensitivity to the active substance, to other
corticosteroids, or to any of the excipients.

Revised: August 2025
AN: 01405/2025
See also sections 4.7 and 4.8.
4.4 Special warnings for each target species
Glucocorticoids can produce symptomatic improvements without treating the
underlying disease. Where appropriate, use of the product should be combined with
treatment of the underlying disease and/or management of the affected animal’s
environment.
4.5 Special precautions for use
Special precautions for use in animals
In cases where a bacterial infection is present the product should be used in
association with suitable antibacterial therapy.
Corticoids such as prednisolone should be used with caution in patients with
hypertension, epilepsy, burns, previous steroid myopathy, in immunocompromised
animals and in young animals as corticosteroids may induce a delayed growth.
Corticoids such as prednisolone, exacerbate proteinaceous catabolism.
Consequently, the product should be carefully administered in old or malnourished
animals.
Special monitoring is required in animals presenting with renal insufficiency. Use only
after careful benefit-risk assessment by the responsible veterinarian.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.